Aprea Therapeutics Inc (APRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aprea Therapeutics Inc (APRE) has a cash flow conversion efficiency ratio of -0.064x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.76 Million) by net assets ($42.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Aprea Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Aprea Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Aprea Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Aprea Therapeutics Inc (APRE) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Aprea Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprea Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FAST TRACK GROUP
NASDAQ:FTRK
|
-0.460x |
|
ODIGMA CONSULTANCY SOLUTIONS LTD
NSE:ODIGMA
|
N/A |
|
Bulletin Resources Ltd
AU:BNR
|
-0.046x |
|
Galilee Energy Ltd
AU:GLL
|
24.798x |
|
IMAGIS Co. Ltd
KQ:115610
|
0.146x |
|
Rovsing A/S
CO:ROV
|
-0.227x |
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
-0.270x |
|
Modern Internasional Tbk
JK:MDRN
|
0.057x |
Annual Cash Flow Conversion Efficiency for Aprea Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aprea Therapeutics Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see APRE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $12.44 Million | $-12.89 Million | -1.036x | -47.60% |
| 2024-12-31 | $19.31 Million | $-13.56 Million | -0.702x | -5.31% |
| 2023-12-31 | $18.26 Million | $-12.18 Million | -0.667x | +31.64% |
| 2022-12-31 | $25.64 Million | $-25.01 Million | -0.975x | -28.13% |
| 2021-12-31 | $49.51 Million | $-37.69 Million | -0.761x | -40.94% |
| 2020-12-31 | $77.40 Million | $-41.80 Million | -0.540x | -151.25% |
| 2019-12-31 | $124.24 Million | $-26.71 Million | -0.215x | -172.51% |
| 2018-12-31 | $-51.44 Million | $-15.25 Million | 0.296x | -24.27% |
| 2017-12-31 | $-35.77 Million | $-14.00 Million | 0.392x | -56.40% |
| 2007-12-31 | $-2.11 Million | $-1.90 Million | 0.898x | -- |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more